Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05381311 · ClinicalTrials.gov registry record
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 1,020
- Enrollment target
NCT05381311 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 1,020 participants.
The verdict
NCT05381311 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 1,020 participants
- Enrollment target
Study Summary
The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This study will also quantify the importance of administration factors related to convenience relative to treatment outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2022-12-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05381311
The ClinicalTrials.gov registry entry for NCT05381311 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05381311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05381311 about?
NCT05381311 is a clinical study titled "Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study". The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for participants with locally-advanced and metastatic hormone-sensitive prostate cancer (mHSPC). This s...
What is the current status of trial NCT05381311?
This trial is currently completed. The enrollment target is 1,020 participants. The study started on 2021-09-03. Estimated completion is 2022-12-11.
Who is sponsoring clinical trial NCT05381311?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.